Frontier Capital Management Co. LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR)

Frontier Capital Management Co. LLC increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 36.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 243,681 shares of the biotechnology company's stock after acquiring an additional 64,527 shares during the period. United Therapeutics makes up approximately 0.8% of Frontier Capital Management Co. LLC's holdings, making the stock its 24th largest holding. Frontier Capital Management Co. LLC owned about 0.55% of United Therapeutics worth $85,980,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Signaturefd LLC boosted its stake in shares of United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after purchasing an additional 30 shares during the period. Parallel Advisors LLC boosted its position in United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after buying an additional 30 shares during the last quarter. Anchor Investment Management LLC grew its stake in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 30 shares in the last quarter. Great Lakes Advisors LLC increased its position in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after acquiring an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after acquiring an additional 33 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Up 4.0 %

UTHR stock opened at $306.96 on Thursday. The firm's 50-day simple moving average is $300.72 and its 200 day simple moving average is $343.05. The stock has a market cap of $13.85 billion, a PE ratio of 13.48, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a fifty-two week low of $260.41 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the business earned $6.17 earnings per share. Equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on UTHR shares. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a report on Monday, April 21st. JPMorgan Chase & Co. cut their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Finally, StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $392.00.

Insider Activity

In related news, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction on Monday, April 14th. The stock was sold at an average price of $285.16, for a total value of $855,480.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at $499,030. The trade was a 63.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,500 shares of company stock worth $24,245,880 over the last 90 days. 11.90% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.